TITLE

Fat-cat salaries are the best way to get the cream

AUTHOR(S)
Pitcher, George
PUB. DATE
May 2003
SOURCE
Marketing Week;5/29/2003, Vol. 26 Issue 22, p27
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the salary of executives in Great Britain. Increase in the remuneration received by executives in the oil industry as a result of the Iraq conflict; Dissention of the public, especially the press, against the increase in pay received by executives; Issue concerning the proposed pay deal of Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline.
ACCESSION #
9970721

 

Related Articles

  • GSK Revisits Exec Pay. Houlton, Sarah // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p28 

    Reports on the plan created by GlaxoSmithKline PLC for compensating senior executives to replace a plan rejected by stockholders in Great Britain. Problem of investors with the original proposal; Changes made to the contracts of other executive directors; Salary and bonus package received by...

  • Fat cat cream goes sour.  // European Chemical News;5/26/2003, Vol. 78 Issue 2054, p5 

    Comments on the decision of GlaxoSmithKline (GSK) shareholders to vote down the proposed remuneration package for chief executive officer Jean-Pierre Garnier. Amount of the proposed package; Argument of shareholders against the proposal; Implication of the GSK vote.

  • Shareholders okay Garnier pay. Beacham, Will // European Chemical News;5/24/2004, Vol. 80 Issue 2101, p9 

    Reports on the approval of the compensation package of Jean-Pierre Garnier, the chief executive officer at GlaxoSmithKline, by shareholders at the British drug group's annual general meeting in May 2004. Value of the compensation package; Potential career changes at the company in 2004 and 2005.

  • EARNING CURVE: MEDICINE.  // Management Today;May2005, p18 

    The article informs about earning of an executive and other staff in the medicare industry. Jean-Pierre Garnier, CEO of pharmaceutical firm GlaxoSmithKline PLC earns £2.4m per annum. A hospital consultant gets a basic pay of £24.6k-£34.5k p.a.

  • Good Science And The Marketplace For Drugs: A Conversation With Jean-Pierre Garnier. Iglehart, John K. // Health Affairs;Jul/Aug2003, Vol. 22 Issue 4, p119 

    Interviews Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline. Expansion of the scope of Medicare's prescription drug benefits; GlaxoSmithKline's drug research and development activities; Challenges posed by the generic market; Future of drug development.

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune International (Europe);3/21/2005, Vol. 151 Issue 5, p20 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

  • GSK Names New Chairman.  // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p174 

    The article announces the appointment of Moncef Slaoui as chairman of research and development at GlaxoSmithKline effective June 1, 2006. Slaoui will report to Chief Executive Officer Jean-Pierre Garnier. Slaoui succeeds Tadataka Yamada who will retire from the company to become executive...

  • GSK makes strides in R&D.  // European Chemical News;12/8/2003, Vol. 79 Issue 2080, p28 

    Reports on the research and development (R&D) achievements of GlaxoSmithKline (GSK) presented by chief executive officer Jean-Pierre Garnier to investors in December 2003. Number of projects in clinical development; Number of chemical entities developed by GSK; R&D innovation launched by the...

  • WISDOM FROM BIG PHARMA'S DR. GLOOM. Lustgarten, Abrahm // Fortune;3/21/2005, Vol. 151 Issue 6, p38 

    Presents an interview with GlaxoSmithKline CEO Jean-Pierre Garnier. Thoughts on challenges facing the pharmaceutical industry, including the development of meaningful drugs; Signing with Human Genome Sciences to use gene sequencing technology to help develope new drugs; Comments on the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics